FDA Approves First-In-Class IL-6R Inhibitor as The First And Only At-Home Subcutaneous ...

The FDA approved Genentech’s Enspryng (satralizumab-mwge) as the first and only at-home subcutaneous treatment for thyroid eye disease (TED), offering patients greater treatment flexibility with demonstrated efficacy and safety.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it.